Inst Diagnosti
Instituto de Diagnóstico S.A. provides health services in Chile. It offers patient information and exams instruction, and online services; specialties services; and outpatient services including urgency, laboratory, imaging, vaccination, blood bank, outpatient procedures, and reproductive medicine unit. The company also provides hospitalization services, such as maternity, adult and pediatric hos… Read more
Inst Diagnosti (INDISA) - Net Assets
Latest net assets as of June 2025: CL$114.04 Billion CLP
Based on the latest financial reports, Inst Diagnosti (INDISA) has net assets worth CL$114.04 Billion CLP as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CL$305.25 Billion) and total liabilities (CL$191.22 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CL$114.04 Billion |
| % of Total Assets | 37.36% |
| Annual Growth Rate | 8.08% |
| 5-Year Change | 28.68% |
| 10-Year Change | 92.43% |
| Growth Volatility | 3.52 |
Inst Diagnosti - Net Assets Trend (2014–2024)
This chart illustrates how Inst Diagnosti's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Inst Diagnosti (2014–2024)
The table below shows the annual net assets of Inst Diagnosti from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CL$109.16 Billion | +4.94% |
| 2023-12-31 | CL$104.02 Billion | +2.28% |
| 2022-12-31 | CL$101.70 Billion | +6.87% |
| 2021-12-31 | CL$95.17 Billion | +12.19% |
| 2020-12-31 | CL$84.82 Billion | +3.55% |
| 2019-12-31 | CL$81.92 Billion | +7.67% |
| 2018-12-31 | CL$76.08 Billion | +10.27% |
| 2017-12-31 | CL$69.00 Billion | +9.43% |
| 2016-12-31 | CL$63.05 Billion | +11.15% |
| 2015-12-31 | CL$56.73 Billion | +13.09% |
| 2014-12-31 | CL$50.16 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inst Diagnosti's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 34.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CL$46.11 Billion | 42.24% |
| Other Components | CL$63.05 Billion | 57.76% |
| Total Equity | CL$109.16 Billion | 100.00% |
Inst Diagnosti Competitors by Market Cap
The table below lists competitors of Inst Diagnosti ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telecom Argentina S.A
PINK:TCMFF
|
$295.01 Million |
|
Jiangxi Huangshanghuang Group Food Co Ltd
SHE:002695
|
$295.14 Million |
|
Phoenix Mecano AG
LSE:0QKP
|
$295.15 Million |
|
Nowtransit Inc
PINK:NOTR
|
$295.18 Million |
|
GHT Co Ltd Class A
SHE:300711
|
$294.90 Million |
|
Tanla Platforms Limited
NSE:TANLA
|
$294.83 Million |
|
FastPartner AB Series D
ST:FPAR-D
|
$294.76 Million |
|
Qingdao Daneng Environmental Protection Equipment Co Ltd
SHG:688501
|
$294.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inst Diagnosti's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 104,019,753,000 to 109,156,351,000, a change of 5,136,598,000 (4.9%).
- Net income of 7,275,926,000 contributed positively to equity growth.
- Dividend payments of 43,688,000 reduced retained earnings.
- Other factors decreased equity by 2,095,640,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CL$7.28 Billion | +6.67% |
| Dividends Paid | CL$43.69 Million | -0.04% |
| Other Changes | CL$-2.10 Billion | -1.92% |
| Total Change | CL$- | 4.94% |
Book Value vs Market Value Analysis
This analysis compares Inst Diagnosti's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.12x to 3.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CL$489.58 | CL$2505.60 | x |
| 2018-12-31 | CL$539.87 | CL$2505.60 | x |
| 2019-12-31 | CL$581.26 | CL$2505.60 | x |
| 2020-12-31 | CL$601.89 | CL$2505.60 | x |
| 2021-12-31 | CL$675.27 | CL$2505.60 | x |
| 2022-12-31 | CL$701.65 | CL$2505.60 | x |
| 2023-12-31 | CL$738.09 | CL$2505.60 | x |
| 2024-12-31 | CL$753.09 | CL$2505.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inst Diagnosti utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.67%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.04%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 2.50x
- Recent ROE (6.67%) is below the historical average (14.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 23.40% | 11.32% | 0.93x | 2.23x | CL$6.72 Billion |
| 2015 | 23.15% | 11.23% | 0.86x | 2.39x | CL$7.46 Billion |
| 2016 | 20.51% | 10.08% | 0.83x | 2.45x | CL$6.63 Billion |
| 2017 | 17.23% | 8.59% | 0.87x | 2.32x | CL$4.99 Billion |
| 2018 | 19.31% | 10.11% | 0.89x | 2.15x | CL$7.09 Billion |
| 2019 | 14.20% | 7.74% | 0.89x | 2.06x | CL$3.44 Billion |
| 2020 | 4.13% | 2.51% | 0.76x | 2.15x | CL$-4.98 Billion |
| 2021 | 21.70% | 10.95% | 0.82x | 2.43x | CL$11.13 Billion |
| 2022 | 12.83% | 6.82% | 0.70x | 2.68x | CL$2.88 Billion |
| 2023 | 0.14% | 0.07% | 0.79x | 2.66x | CL$-10.26 Billion |
| 2024 | 6.67% | 3.04% | 0.88x | 2.50x | CL$-3.64 Billion |
Industry Comparison
This section compares Inst Diagnosti's net assets metrics with peer companies in the Medical Care Facilities industry.
No peer company data available for comparison.